Guj. Terce Labs. — 360° view

Guj. Terce Labs, a company in the Pharmaceuticals industry, reported revenue of ₹13 crore and net profit of ₹1.32 crore for the September 2026 quarter.

Guj. Terce Labs. (BSE: GUJTERC) closed at ₹41.00 on 20 Nov 2026, down 4.8% over the past year. Its market capitalisation is ₹32 crore and it trades at 14.9 times earnings.

Share price
₹41.00 (20 Nov 2026)
Market cap
₹32 Cr (20 Nov 2026)
P/E
14.93 (20 Nov 2026)
Revenue
₹13 Cr (September 2026 quarter)
Net profit
₹1 Cr (September 2026 quarter)
ROCE
39.2% (FY26)
ROE
30.2% (FY26)
Book value
₹14.0 (FY26)
Dividend yield
0.00% (FY26)
52-week high / low
₹50.00 / ₹29.00 (20 Nov 2026)
1-year return
-4.8% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
BSE: GUJTERC

Incorporated in 1985. Gujarat Terce Laboratories Ltd is engaged in development, manufacturing, marketing and distribution of medicines, healthcare products and branded generics

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.